# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Josh Schimmer reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight.
Leerink Partners analyst Lili Nsongo initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform rating and ...
HC Wainwright & Co. analyst Ed Arce maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target...
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight.
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of...
HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price ta...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this yearARCT-810 to exp...